Asian Biosecurity Policies and Practices Highlighted by BioInformatics at Global Biosecurity Conference

Share Article

Dr. Tamara Zemlo, Director of Syndicated Research at BioInformatics, LLC, highlighted biosecurity policies and practices of Asian life science labs at the recent conference "Developing Options for Global Biosecurity: Assessing Progress and Evaluating New Mechanisms." The event, held March 6 and 7, was sponsored by the Partnership for Global Security and supported by The Carnegie Corporation of New York.

Dr. Tamara Zemlo, Director of Syndicated Research at BioInformatics, LLC, highlighted biosecurity policies and practices of Asian life science labs at the recent conference "Developing Options for Global Biosecurity: Assessing Progress and Evaluating New Mechanisms." The event, held March 6 and 7, was sponsored by the Partnership for Global Security and supported by The Carnegie Corporation of New York.

Dr. Zemlo was among sixteen invited speakers at the conference, the objective of which was to define the critical issues associated with developing an integrated global biosecurity network. During the first day of the two-day conference, participants sought to examine the scope of existing biosecurity activities and initiatives, outline the new challenges arising from the rapid growth of the biotechnology sector around the globe, and consider a wide range of ideas that can facilitate the harmonization of global biosecurity approaches and mechanisms.

The presentation highlighted the results of a 2006 study conducted for Sandia National Laboratories by BioInformatics (http://www.gene2drug.com), an Arlington, Virginia-based research and consulting firm, outlining biosecurity practices in Asia, Latin America, Eastern Europe, and the Middle East. Based on responses from scientists in sixteen Asian countries, the report finds that current biosafety measures may be inadequate, particularly the use of the appropriate biosafety level.

As Dr. Zemlo commented, "Biosafety level (BSL) 2 practices are often employed for research involving BSL 3 agents. HIV, Japanese encephalitis, avian influenza, and severe acute respiratory syndrome (SARS) should be studied typically under BSL 3 practices, however the majority of respondents to our study use BSL 2 precautions for these dangerous pathogens." In her presentation Dr. Zemlo profiled the types of infectious agents studied, risk perceptions of researchers working with key infectious agents, the management of biosecurity regulations, and biosecurity practices in Asian countries.

BioInformatics used its research expertise in biodefense to create this report on Asian biosafety and biosecurity research practices in support of Sandia National Laboratories Biological Weapons Nonproliferation Department. Dr. Zemlo, an expert on the biodefense and biosecurity markets, also wrote the recently published report "Market Opportunities in Biodefense Research: Trends & Forecasts." For this report, BioInformatics, LLC asked hundreds of current and future biodefense researchers in North Amercia about the products they use. This unique report identifies what current, funded biodefense researchers are buying, what they still need, and how life science suppliers can best meet those needs. The report is a sequel to one published in 2004, "Market Opportunities in Biodefense Research."

For more information on Market Opportunities in Biodefense Research: Trends & Forecasts, please visit http://www.gene2drug.com/reports. The full report on Asian biosafety and biosecurity is available online at https://www.biosecurity.sandia.gov/docs/2006/asia-summary-sand-report-final.pdf.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is a market research and consulting firm that supports marketing, sales and R&D executives in the life science, medical device and pharmaceutical industries through published research reports, custom research and consulting. It also sponsors the world's largest market research panel of scientific customers -- The Science Advisory Board (http://www.scienceboard.net) -- which consists of more than 32,000 scientists, physicians and other life science and medical professionals from 62 countries who participate in surveys that address emerging technologies, test customer reactions to new product concepts, measure brand awareness and assess advertising effectiveness.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

AMANDA DONATHEN
Visit website